By Benjamin Chiou
Date: Monday 12 Jan 2026
(Sharecast News) - Shares in Nasdaq-listed Abivax soared in pre-market trading on Monday after reports emerged that pharma giant Eli Lilly was preparing a $17.5bn bid for the Paris-based biotech firm.
| Currency | US Dollars |
| Share Price | $ 1,078.52 |
| Closing Price Change | $ 37.23 |
| % Change | 0.00 % |
| 52 Week High | $1,109.94 |
| 52 Week Low | $625.65 |
| Volume | 0 |
| Shares Issued | 948.17m |
| Beta | 0.02 |
| RiskGrade | 179 |
| Strong Buy | 12 |
| Buy | 12 |
| Neutral | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 31 |

You are here: research